



Clinical trial results:

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease

Summary

EudraCT number	2012-001398-97
Trial protocol	FI SK PL GR LT BE IT NL DK AT HU PT ES CZ EE IS GB DE BG
Global end of trial date	SE LV IE NO 11 November 2016

Results information

Result version number	v2 (current)
This version publication date	19 January 2018
First version publication date	26 November 2017

Version creation reason

Trial information

Trial identification

Sponsor protocol code	20110118
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01764633
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Amgen Inc.
Sponsor organisation address	One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
Public contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com
Scientific contact	IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 January 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	11 November 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) regulations/guidelines.

All subjects provided written informed consent before undergoing any study-related procedures, including screening procedures.

The study and all amendments were reviewed by an independent ethics committees (IEC) or institutional review board (IRB) at each center.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 February 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 325
Country: Number of subjects enrolled	China: 1021
Country: Number of subjects enrolled	Hong Kong: 46
Country: Number of subjects enrolled	India: 266
Country: Number of subjects enrolled	Japan: 429
Country: Number of subjects enrolled	Korea, Republic of: 181
Country: Number of subjects enrolled	Malaysia: 65
Country: Number of subjects enrolled	New Zealand: 92
Country: Number of subjects enrolled	Philippines: 294
Country: Number of subjects enrolled	Singapore: 35
Country: Number of subjects enrolled	South Africa: 937
Country: Number of subjects enrolled	Taiwan: 144
Country: Number of subjects enrolled	Austria: 173
Country: Number of subjects enrolled	Belgium: 245
Country: Number of subjects enrolled	Bulgaria: 292
Country: Number of subjects enrolled	Czech Republic: 2221
Country: Number of subjects enrolled	Denmark: 481

Country: Number of subjects enrolled	Estonia: 164
Country: Number of subjects enrolled	Finland: 242
Country: Number of subjects enrolled	France: 354
Country: Number of subjects enrolled	Germany: 738
Country: Number of subjects enrolled	Greece: 271
Country: Number of subjects enrolled	Hungary: 980
Country: Number of subjects enrolled	Iceland: 90
Country: Number of subjects enrolled	Ireland: 55
Country: Number of subjects enrolled	Israel: 239
Country: Number of subjects enrolled	Italy: 393
Country: Number of subjects enrolled	Latvia: 144
Country: Number of subjects enrolled	Lithuania: 131
Country: Number of subjects enrolled	Netherlands: 998
Country: Number of subjects enrolled	Norway: 111
Country: Number of subjects enrolled	Poland: 2467
Country: Number of subjects enrolled	Portugal: 273
Country: Number of subjects enrolled	Romania: 193
Country: Number of subjects enrolled	Russian Federation: 1565
Country: Number of subjects enrolled	Slovakia: 638
Country: Number of subjects enrolled	Spain: 362
Country: Number of subjects enrolled	Sweden: 474
Country: Number of subjects enrolled	Switzerland: 175
Country: Number of subjects enrolled	Turkey: 189
Country: Number of subjects enrolled	Ukraine: 1186
Country: Number of subjects enrolled	United Kingdom: 1491
Country: Number of subjects enrolled	Argentina: 269
Country: Number of subjects enrolled	Brazil: 693
Country: Number of subjects enrolled	Chile: 196
Country: Number of subjects enrolled	Colombia: 377
Country: Number of subjects enrolled	Mexico: 288
Country: Number of subjects enrolled	Canada: 558
Country: Number of subjects enrolled	United States: 4013
Worldwide total number of subjects	27564
EEA total number of subjects	13981

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	15310
From 65 to 84 years	12225
85 years and over	29

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at 1242 clinical centers in 49 countries in the regions of Europe (62.9%), North America (16.6%), Asia Pacific (13.9%), and Latin America (6.6%) from 08 February 2013 to 05 June 2015.

Pre-assignment

Screening details:

Eligible participants were randomized in a 1:1 ratio to receive either subcutaneous (SC) evolocumab or placebo. Randomization was stratified by the final screening low-density lipoprotein cholesterol (LDL-C) level (< 85 mg/dL vs ≥ 85 mg/dL) and by geographical region.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Data analyst, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Arm title	Evolocumab
------------------	------------

Arm description:

Participants received evolocumab subcutaneous injections either 140 mg Q2W or 420 mg QM according to their own preference.

Arm type	Experimental
Investigational medicinal product name	Evolocumab
Investigational medicinal product code	AMG 145
Other name	Repatha
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered subcutaneously at 140 mg Q2W or 420 mg QM using a spring-based prefilled 1.0 mL autoinjector/pen.

Number of subjects in period 1	Placebo	Evolocumab
Started	13780	13784
Received Treatment	13756	13769
Completed	13662	13691
Not completed	118	93
Consent withdrawn by subject	105	88
Lost to follow-up	13	5

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.	
Reporting group title	Evolocumab
Reporting group description:	
Participants received evolocumab subcutaneous injections either 140 mg Q2W or 420 mg QM according to their own preference.	

Reporting group values	Placebo	Evolocumab	Total
Number of subjects	13780	13784	27564
Age, Customized			
Units: Subjects			
< 65 years	7687	7623	15310
≥ 65 years	6093	6161	12254
Age Continuous			
Units: years			
arithmetic mean	62.5	62.5	
standard deviation	± 8.9	± 9.1	-
Sex: Female, Male			
Units: Subjects			
Female	3382	3387	6769
Male	10398	10397	20795
Race/Ethnicity, Customized			
Units: Subjects			
American Indian or Alaska Native	80	60	140
Asian	1349	1374	2723
Black or African American	352	317	669
Native Hawaiian or Other Pacific Islander	11	15	26
White	11710	11748	23458
Multiple	12	19	31
Other	266	251	517
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1084	1093	2177
Not Hispanic or Latino	12694	12688	25382
Unknown or Not Reported	2	3	5
Final Screening Low-density Lipoprotein Cholesterol			
Units: Subjects			
< 85 mg/dL	4803	4809	9612
≥ 85 mg/dL	8977	8975	17952
Geographical Region			
Units: Subjects			
Europe	8669	8667	17336
North America	2284	2286	4570

Latin America	910	913	1823
Asia Pacific	1917	1918	3835

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.	
Reporting group title	Evolocumab
Reporting group description:	
Participants received evolocumab subcutaneous injections either 140 mg Q2W or 420 mg QM according to their own preference.	

Primary: Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization

End point title	Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization
End point description:	
All deaths and potential endpoint events were adjudicated by an independent external Clinical Events Committee (CEC) led by the Thrombolysis in Myocardial Infarction (TIMI) Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". Time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.	
End point type	Primary
End point timeframe:	
Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.	

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[1]	13784 ^[2]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13276, 13349)	3.11 (2.82 to 3.40)	2.74 (2.47 to 3.01)		
KM estimate at 12 months (N = 12822, 12937)	6.01 (5.61 to 6.41)	5.31 (4.93 to 5.68)		
KM estimate at 18 months (N = 11837, 12034)	8.32 (7.86 to 8.78)	7.25 (6.81 to 7.68)		
KM estimate at 24 months (N = 7589, 7743)	10.66 (10.12 to 11.19)	9.13 (8.63 to 9.63)		
KM estimate at 30 months (N = 3589, 3652)	12.72 (12.08 to 13.35)	10.91 (10.31 to 11.50)		
KM estimate at 36 months (N = 672, 681)	14.64 (13.76 to 15.50)	12.57 (11.70 to 13.42)		

Notes:

[1] - N = the number of subjects at risk

[2] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
-----------------------------------	------------------

Statistical analysis description:

The primary endpoint was compared between treatment groups at a significance level of 0.05. The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[3]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.79
upper limit	0.92

Notes:

[3] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to Cardiovascular Death, Myocardial Infarction, or Stroke

End point title	Time to Cardiovascular Death, Myocardial Infarction, or Stroke
-----------------	--

End point description:

All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". Time to cardiovascular death, myocardial infarction, or stroke was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.

End point type	Secondary
----------------	-----------

End point timeframe:

Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[4]	13784 ^[5]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13447, 13499)	1.86 (1.63 to 2.08)	1.65 (1.44 to 1.86)		
KM estimate at 12 months (N = 13140, 13240)	3.68 (3.36 to 3.99)	3.10 (2.81 to 3.38)		
KM estimate at 18 months (N = 12257, 12422)	5.18 (4.81 to 5.55)	4.29 (3.95 to 4.62)		
KM estimate at 24 months (N = 7923, 8066)	6.83 (6.39 to 7.26)	5.47 (5.08 to 5.86)		
KM estimate at 30 months (N = 3785, 3837)	8.31 (7.78 to 8.84)	6.66 (6.19 to 7.14)		
KM estimate at 36 months (N = 717, 713)	9.93 (9.16 to 10.69)	7.90 (7.17 to 8.63)		

Notes:

[4] - N = the number of subjects at risk

[5] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
----------------------------	------------------

Statistical analysis description:

If the primary endpoint reached statistical significance at the 0.05 level, the key secondary endpoint (composite of cardiovascular death, myocardial infarction, and stroke) was tested at a significance level of 0.05.

The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[6]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	0.88

Notes:

[6] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to Cardiovascular Death

End point title	Time to Cardiovascular Death
-----------------	------------------------------

End point description:

All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". Cardiovascular death includes death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure (HF), death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes. Time to cardiovascular death was defined as the time from randomization to the date of cardiovascular death

and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on the last confirmed survival status date.

End point type	Secondary
End point timeframe:	
Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.	

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[7]	13784 ^[8]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13688, 13698)	0.40 (0.29 to 0.50)	0.39 (0.29 to 0.50)		
KM estimate at 12 months (N = 13590, 13598)	0.82 (0.67 to 0.97)	0.79 (0.64 to 0.94)		
KM estimate at 18 months (N = 12844, 12869)	1.19 (1.01 to 1.37)	1.20 (1.01 to 1.38)		
KM estimate at 24 months (N = 8427, 8441)	1.57 (1.36 to 1.79)	1.64 (1.42 to 1.85)		
KM estimate at 30 months (N = 4081, 4043)	1.99 (1.72 to 2.26)	2.11 (1.83 to 2.39)		
KM estimate at 36 months (N = 783, 767)	2.39 (1.98 to 2.80)	2.49 (2.09 to 2.88)		

Notes:

[7] - N = the number of subjects at risk

[8] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
Statistical analysis description:	
If the primary and key secondary endpoint reached a statistical significance level of 0.05, then the endpoint of cardiovascular death was tested at a significance level of 0.05.	
The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).	
Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6188 ^[9]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.88
upper limit	1.25

Notes:

[9] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to All Cause Death

End point title	Time to All Cause Death
-----------------	-------------------------

End point description:

Time to all-cause death was defined as the time from randomization to the date of death and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on the last confirmed survival status date.

End point type	Secondary
----------------	-----------

End point timeframe:

Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[10]	13784 ^[11]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13688, 13698)	0.62 (0.49 to 0.75)	0.55 (0.43 to 0.68)		
KM estimate at 12 months (N = 13590, 13598)	1.29 (1.10 to 1.47)	1.26 (1.07 to 1.44)		
KM estimate at 18 months (N = 12844, 12869)	1.96 (1.73 to 2.19)	1.94 (1.71 to 2.17)		
KM estimate at 24 months (N = 8427, 8441)	2.78 (2.49 to 3.06)	2.81 (2.52 to 3.10)		
KM estimate at 30 months (N = 4081, 4043)	3.48 (3.12 to 3.83)	3.63 (3.27 to 3.98)		
KM estimate at 36 months (N = 783, 767)	4.28 (3.74 to 4.82)	4.75 (4.16 to 5.34)		

Notes:

[10] - N = the number of subjects at risk

[11] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
----------------------------	------------------

Statistical analysis description:

If the primary, key secondary and endpoint cardiovascular death reached a statistical significance level of 0.05, then the endpoint of all-cause death was tested at a significance level of 0.04 and remaining secondary endpoints at an overall significant level of 0.01 by applying the Hochberg method.

The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
-------------------	----------------------

Number of subjects included in analysis	27564
---	-------

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	superiority
---------------	-------------

P-value	= 0.5368 ^[12]
---------	--------------------------

Method	Logrank
--------	---------

Parameter estimate	Hazard ratio (HR)
--------------------	-------------------

Point estimate	1.04
----------------	------

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.91
upper limit	1.19

Notes:

[12] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to First Myocardial Infarction

End point title	Time to First Myocardial Infarction
-----------------	-------------------------------------

End point description:

All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". The diagnosis of myocardial infarction required the combination of:

- Evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and
- Supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery Imaging.

Time to first myocardial infarction was defined as the time from randomization to the date of the first MI and was analyzed using Kaplan-Meier survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.

End point type	Secondary
----------------	-----------

End point timeframe:

Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[13]	13784 ^[14]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13497, 13536)	1.14 (0.97 to 1.32)	1.06 (0.88 to 1.23)		
KM estimate at 12 months (N = 13226, 13312)	2.39 (2.13 to 2.64)	1.90 (1.67 to 2.13)		
KM estimate at 18 months (N = 12374, 12522)	3.33 (3.03 to 3.63)	2.55 (2.28 to 2.81)		
KM estimate at 24 months (N = 8031, 8137)	4.30 (3.95 to 4.65)	3.21 (2.90 to 3.51)		
KM estimate at 30 months (N = 3839, 3883)	5.25 (4.82 to 5.67)	3.83 (3.47 to 4.19)		
KM estimate at 36 months (N = 733, 726)	6.28 (5.67 to 6.89)	4.41 (3.85 to 4.96)		

Notes:

[13] - N = the number of subjects at risk

[14] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
----------------------------	------------------

Statistical analysis description:

If the primary, key secondary, and endpoint of cardiovascular death reached a statistical significance

level of 0.05, then the endpoint of all-cause death was tested at a significance level of 0.04 and remaining secondary endpoints were tested at an overall significance level of 0.01 by applying the Hochberg method.

The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[15]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	0.82

Notes:

[15] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to First Stroke

End point title	Time to First Stroke
-----------------	----------------------

End point description:

All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction. Time to first stroke was defined as the time from randomization to the date of the stroke and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.

End point type	Secondary
----------------	-----------

End point timeframe:

Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[16]	13784 ^[17]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13587, 13631)	0.50 (0.38 to 0.61)	0.31 (0.22 to 0.41)		
KM estimate at 12 months (N = 13428, 13470)	0.85 (0.69 to 1.00)	0.70 (0.56 to 0.84)		
KM estimate at 18 months (N = 12626, 12703)	1.30 (1.11 to 1.50)	1.05 (0.88 to 1.22)		
KM estimate at 24 months (N = 8240, 8304)	1.80 (1.57 to 2.04)	1.36 (1.16 to 1.56)		
KM estimate at 30 months (N = 3977, 3967)	2.15 (1.88 to 2.43)	1.71 (1.46 to 1.96)		

KM estimate at 36 months (N = 757, 741)	2.60 (2.20 to 3.00)	2.18 (1.76 to 2.59)		
---	---------------------	---------------------	--	--

Notes:

[16] - N = the number of subjects at risk

[17] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
-----------------------------------	------------------

Statistical analysis description:

If the primary, key secondary, and endpoint of cardiovascular death reached a statistical significance level of 0.05, then the endpoint of all-cause death was tested at a significance level of 0.04 and remaining secondary endpoints were tested at an overall significance level of 0.01 by applying the Hochberg method.

The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0101 ^[18]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	0.95

Notes:

[18] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to First Coronary Revascularization

End point title	Time to First Coronary Revascularization
-----------------	--

End point description:

All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the "Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction". Time to first coronary revascularization was defined as the time from randomization to the date of the coronary revascularization and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.

End point type	Secondary
----------------	-----------

End point timeframe:

Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[19]	13784 ^[20]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13390, 13454)	1.87 (1.65 to 2.10)	1.60 (1.39 to 1.81)		
KM estimate at 12 months (N = 13029, 13130)	3.71 (3.39 to 4.02)	3.13 (2.84 to 3.42)		
KM estimate at 18 months (N = 12097, 12283)	5.20 (4.82 to 5.57)	4.16 (3.83 to 4.50)		
KM estimate at 24 months (N = 7812, 7952)	6.57 (6.14 to 7.00)	5.22 (4.84 to 5.61)		
KM estimate at 30 months (N = 3718, 3768)	7.91 (7.39 to 8.42)	6.13 (5.68 to 6.58)		
KM estimate at 36 months (N = 704, 710)	9.17 (8.46 to 9.87)	7.01 (6.36 to 7.65)		

Notes:

[19] - N = the number of subjects at risk

[20] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
----------------------------	------------------

Statistical analysis description:

If the primary, key secondary, and endpoint of cardiovascular death reached a statistical significance level of 0.05, then the endpoint of all-cause death was tested at a significance level of 0.04 and remaining secondary endpoints were tested at an overall significance level of 0.01 by applying the Hochberg method.

The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 ^[21]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	0.86

Notes:

[21] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure

End point title	Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure
-----------------	---

End point description:

All events were adjudicated by an independent external CEC led by the TIMI Study Group using standardized definitions. HF hospitalization was defined as an event that met all of the following criteria:

1. Admitted to hospital with a primary diagnosis of HF
2. In hospital for at least 24 hours

3. Documented new or worsening symptoms due to HF, including at least 1 of the following:
 - Dyspnea
 - Decreased exercise tolerance
 - Fatigue
 - Other symptoms of worsened end-organ perfusion or volume overload
 4. Evidence of new or worsening HF consisting of at least 2 physical exam findings or 1 physical exam finding and at least 1 laboratory criterion
 5. Received new or increased treatment for HF.
- Time to CV death or first hospitalization for worsening HF was defined as the time from randomization to the first occurrence of any component of the endpoint analyzed using KM analysis. Participants with no event were censored based on last non-fatal potential endpoint collection date.

End point type	Secondary
----------------	-----------

End point timeframe:

Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[22]	13784 ^[23]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13592, 13635)	0.79 (0.64 to 0.93)	0.64 (0.51 to 0.77)		
KM estimate at 12 months (N = 13455, 13481)	1.35 (1.16 to 1.54)	1.29 (1.10 to 1.48)		
KM estimate at 18 months (N = 12664, 12710)	1.99 (1.75 to 2.22)	1.99 (1.76 to 2.22)		
KM estimate at 24 months (N = 8265, 8304)	2.70 (2.41 to 2.98)	2.64 (2.36 to 2.92)		
KM estimate at 30 months (N = 3983, 3967)	3.45 (3.09 to 3.81)	3.31 (2.97 to 3.65)		
KM estimate at 36 months (N = 761, 737)	4.03 (3.50 to 4.55)	4.13 (3.57 to 4.68)		

Notes:

[22] - N = the number of subjects at risk

[23] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
----------------------------	------------------

Statistical analysis description:

If the primary, key secondary, and endpoint of cardiovascular death reached a statistical significance level of 0.05, then the endpoint of all-cause death was tested at a significance level of 0.04 and remaining secondary endpoints were tested at an overall significance level of 0.01 by applying the Hochberg method.

The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8179 ^[24]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.98

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	1.13

Notes:

[24] - Two-sided log-rank test stratified by randomization stratification factors.

Secondary: Time to First Ischemic Fatal or non-Fatal Stroke or Transient Ischemic Attack

End point title	Time to First Ischemic Fatal or non-Fatal Stroke or Transient Ischemic Attack
-----------------	---

End point description:

All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions. Ischemic stroke was defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Transient ischemic attack (TIA) was defined as a transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia, without acute infarction. Time to first ischemic fatal or non-fatal stroke or TIA was defined as the time from randomization to the first occurrence of any component of the endpoint and was analyzed using KM survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.

End point type	Secondary
----------------	-----------

End point timeframe:

Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

End point values	Placebo	Evolocumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13780 ^[25]	13784 ^[26]		
Units: percentage of participants				
number (confidence interval 95%)				
KM estimate at 6 months (N = 13569, 13614)	0.61 (0.48 to 0.73)	0.42 (0.31 to 0.53)		
KM estimate at 12 months (N = 13394, 13445)	1.05 (0.88 to 1.22)	0.83 (0.67 to 0.98)		
KM estimate at 18 months (N = 12588, 12671)	1.52 (1.32 to 1.73)	1.18 (1.00 to 1.37)		
KM estimate at 24 months (N = 8209, 8279)	2.05 (1.81 to 2.30)	1.46 (1.25 to 1.66)		
KM estimate at 30 months (N = 3958, 3954)	2.40 (2.11 to 2.68)	1.92 (1.65 to 2.19)		
KM estimate at 36 months (N = 756, 738)	2.81 (2.41 to 3.21)	2.48 (2.01 to 2.95)		

Notes:

[25] - N = the number of subjects at risk

[26] - N = the number of subjects at risk

Statistical analyses

Statistical analysis title	Primary Analysis
----------------------------	------------------

Statistical analysis description:

If the primary, key secondary, and endpoint of cardiovascular death reached a statistical significance level of 0.05, then the endpoint of all-cause death was tested at a significance level of 0.04 and

remaining secondary endpoints were tested at an overall significance level of 0.01 by applying the Hochberg method.

The hazard ratio is based on a Cox model stratified by the randomization stratification factors (final screening LDL-C level and region).

Comparison groups	Placebo v Evolocumab
Number of subjects included in analysis	27564
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0035 ^[27]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	0.92

Notes:

[27] - Two-sided log-rank test stratified by randomization stratification factors.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the first dose of study drug to the end of study. The median duration of follow-up was 26 months.

Adverse event reporting additional description:

Deaths by any cause were adjudicated efficacy endpoints in this study and were summarized as a secondary endpoint. Events that were negatively adjudicated (did not meet the definitions of an endpoint), were reclassified as an adverse event or serious adverse event.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	Evolocumab
-----------------------	------------

Reporting group description:

Participants received evolocumab subcutaneous injections either 140 mg Q2W or 420 mg QM according to their own preference.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.

Serious adverse events	Evolocumab	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	3410 / 13769 (24.77%)	3404 / 13756 (24.75%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma gastric			

subjects affected / exposed	4 / 13769 (0.03%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of appendix			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	17 / 13769 (0.12%)	12 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 17	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal adenoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal gland cancer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal cancer stage III			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal neoplasm			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anogenital warts			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma stage I			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell polymphocytic leukaemia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	4 / 13769 (0.03%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	1 / 5	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basosquamous carcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastric neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign gastrointestinal neoplasm			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign lung neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of adrenal gland			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of prostate			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of spinal cord			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign pancreatic neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct cancer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign renal neoplasm			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary adenoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder adenocarcinoma stage III			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	12 / 13769 (0.09%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 12	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder adenocarcinoma stage unspecified			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer recurrent			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage 0, with cancer in situ			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage I, with cancer in situ			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			

subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer stage III			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder papilloma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			
subjects affected / exposed	9 / 13769 (0.07%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 9	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma recurrent			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma stage I			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma stage II			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma stage III			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Bladder transitional cell carcinoma stage IV			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain cancer metastatic			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain neoplasm malignant			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	6 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer female			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer in situ			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer recurrent			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial carcinoma			

subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burkitt's lymphoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoid tumour pulmonary			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix carcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholesteatoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choroid melanoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			

subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic myeloid leukaemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer			
subjects affected / exposed	11 / 13769 (0.08%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 12	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer metastatic			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer stage I			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer stage III			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenocarcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer metastatic			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatofibrosarcoma protuberans			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ductal adenocarcinoma of pancreas			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenoma			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fallopian tube cancer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Follicular thyroid cancer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric adenoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer			
subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer stage 0			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer stage IV			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal carcinoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal tumour			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	1 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma multiforme			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemangiopericytoma			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cancer			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular carcinoma			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hodgkin's disease			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal papillary mucinous neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal proliferative breast lesion			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal papillary-mucinous carcinoma of pancreas			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive breast carcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	2 / 13769 (0.01%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer			

subjects affected / exposed	6 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large cell lung cancer stage III			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer metastatic			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer stage 0			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer stage IV			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal squamous cell carcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip and/or oral cavity cancer			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip and/or oral cavity cancer stage III			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lip squamous cell carcinoma			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liposarcoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	13 / 13769 (0.09%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 14	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma metastatic			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage I			
subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage III			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage IV			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic			

subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung carcinoma cell type unspecified stage I			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung carcinoma cell type unspecified stage II			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung carcinoma cell type unspecified stage III			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung carcinoma cell type unspecified stage IV			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	1 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	19 / 13769 (0.14%)	15 / 13756 (0.11%)	
occurrences causally related to treatment / all	0 / 21	1 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung squamous cell carcinoma metastatic			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Lung squamous cell carcinoma stage I			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung squamous cell carcinoma stage III			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoproliferative disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant anorectal neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant ascites			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma in situ			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma of sites other			

than skin			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant mesenteric neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of pleura			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm of renal pelvis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant peritoneal neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant urinary tract neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma benign			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesothelioma			

subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesothelioma malignant			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to adrenals			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to bone			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to liver			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lung			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to lymph nodes			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to pleura			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to spine			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastasis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic bronchial carcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelofibrosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm progression			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm prostate			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma metastatic			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Hodgkin's lymphoma			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			

subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer metastatic			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma metastatic			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal adenocarcinoma			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal squamous cell carcinoma			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral cavity cancer metastatic			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral papilloma			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal cancer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal squamous cell carcinoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian adenoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer stage II			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian epithelial cancer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	5 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	1 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma metastatic			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary cystadenoma lymphomatosum			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroid tumour benign			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile cancer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phaeochromocytoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal cancer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal cancer stage IV			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal neoplasm benign			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasmacytoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural mesothelioma malignant			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polycythaemia vera			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	41 / 13769 (0.30%)	40 / 13756 (0.29%)	
occurrences causally related to treatment / all	3 / 42	0 / 42	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 6	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage I			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage II			

subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage IV			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			
subjects affected / exposed	6 / 13769 (0.04%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 6	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	2 / 13769 (0.01%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 2	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer stage III			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer stage IV			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal adenoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			

subjects affected / exposed	9 / 13769 (0.07%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 11	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer metastatic			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer stage I			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	4 / 13769 (0.03%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma stage I			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma stage II			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma stage III			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal oncocytoma			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal neoplasm			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland adenoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoma metastatic			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schwannoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer			
subjects affected / exposed	5 / 13769 (0.04%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer limited stage			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer metastatic			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestine carcinoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue sarcoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spindle cell sarcoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	0 / 13769 (0.00%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of head and neck			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin			

subjects affected / exposed	5 / 13769 (0.04%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 13769 (0.00%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the vulva			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid cancer metastatic			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Transitional cell cancer of the renal pelvis and ureter			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Undifferentiated sarcoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteral neoplasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine cancer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord neoplasm			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer recurrent			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated hypertension			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aneurysm			
subjects affected / exposed	0 / 13769 (0.00%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiopathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiosclerosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			
subjects affected / exposed	27 / 13769 (0.20%)	27 / 13756 (0.20%)	
occurrences causally related to treatment / all	0 / 28	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm rupture			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic stenosis			

subjects affected / exposed	7 / 13769 (0.05%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 7	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic thrombosis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial occlusive disease			
subjects affected / exposed	1 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure fluctuation			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	5 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cryoglobulinaemia			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	7 / 13769 (0.05%)	14 / 13756 (0.10%)	
occurrences causally related to treatment / all	0 / 7	1 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	4 / 13769 (0.03%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism arterial			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism venous			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granulomatosis with polyangiitis			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	2 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	56 / 13769 (0.41%)	41 / 13756 (0.30%)	
occurrences causally related to treatment / all	2 / 59	1 / 41	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive emergency			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	15 / 13769 (0.11%)	12 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 15	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	9 / 13769 (0.07%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	1 / 12	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery occlusion			

subjects affected / exposed	5 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			
subjects affected / exposed	31 / 13769 (0.23%)	22 / 13756 (0.16%)	
occurrences causally related to treatment / all	0 / 41	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leriche syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphocele			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedema			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant hypertension			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurogenic shock			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			

subjects affected / exposed	9 / 13769 (0.07%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic venous thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	94 / 13769 (0.68%)	82 / 13756 (0.60%)	
occurrences causally related to treatment / all	1 / 113	0 / 96	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery aneurysm			
subjects affected / exposed	5 / 13769 (0.04%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery dissection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			
subjects affected / exposed	20 / 13769 (0.15%)	16 / 13756 (0.12%)	
occurrences causally related to treatment / all	0 / 21	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	27 / 13769 (0.20%)	33 / 13756 (0.24%)	
occurrences causally related to treatment / all	0 / 30	0 / 37	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral circulatory failure			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	35 / 13769 (0.25%)	39 / 13756 (0.28%)	
occurrences causally related to treatment / all	0 / 41	0 / 47	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	16 / 13769 (0.12%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 21	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poor peripheral circulation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renovascular hypertension			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock haemorrhagic			

subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery embolism			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian artery stenosis			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subclavian steal syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior vena cava syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Takayasu's arteritis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporal arteritis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thromboangiitis obliterans			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose ulceration			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular insufficiency			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stenosis			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasodilatation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vena cava thrombosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Abscess drainage			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve replacement			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia prophylaxis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial catheterisation			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula operation			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma prophylaxis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ablation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker insertion			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac rehabilitation therapy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac resynchronisation therapy			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary arterial stent insertion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery bypass			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary revascularisation			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Elective procedure			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterostomy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Finger amputation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture treatment			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric banding reversal			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemostasis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hospitalisation			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator insertion			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia repair			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia repair			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal polypectomy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine anastomosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leg amputation			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open reduction of fracture			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Percutaneous coronary intervention			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery bypass			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plastic surgery to the face			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Preoperative care			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctectomy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rehabilitation therapy			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal anaesthesia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stent placement			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Therapy cessation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe amputation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transcatheter aortic valve implantation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transurethral prostatectomy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia repair			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral operation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	8 / 13769 (0.06%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breakthrough pain			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site extravasation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	42 / 13769 (0.31%)	49 / 13756 (0.36%)	
occurrences causally related to treatment / all	0 / 43	1 / 53	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complication associated with device			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cyst rupture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug intolerance			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug withdrawal syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exercise tolerance decreased			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fat necrosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	5 / 13769 (0.04%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site inflammation			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated hernia			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mass			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device discomfort			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	4 / 13769 (0.03%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			

subjects affected / exposed	109 / 13769 (0.79%)	133 / 13756 (0.97%)	
occurrences causally related to treatment / all	1 / 125	0 / 152	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pacemaker generated arrhythmia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral swelling			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	5 / 13769 (0.04%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sensation of foreign body			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue inflammation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strangulated hernia			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical failure			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent restenosis			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent stenosis			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Allergy to arthropod sting			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic shock			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food allergy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mite allergy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcoidosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant rejection			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Abstains from alcohol			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disability			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Substance abuser			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social stay hospitalisation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Adnexa uteri mass			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			
subjects affected / exposed	30 / 13769 (0.22%)	26 / 13756 (0.19%)	
occurrences causally related to treatment / all	0 / 30	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast dysplasia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Breast enlargement			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast pain			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical dysplasia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical polyp			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervix disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystocele			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial hyperplasia			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial thickening			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Genital haemorrhage			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Male genital tract fistula			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Menorrhagia			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metrorrhagia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic pain			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postmenopausal haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Priapism			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			

subjects affected / exposed	1 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatomegaly			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive tract disorder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal cyst			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal oedema			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spermatic cord inflammation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine atony			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine enlargement			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine haemorrhage			

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polyp			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulvar dysplasia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulvovaginal pruritus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acquired diaphragmatic eventration			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute pulmonary oedema			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory distress syndrome			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	11 / 13769 (0.08%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 13	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Apnoea			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	8 / 13769 (0.06%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 8	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma-chronic obstructive pulmonary disease overlap syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atelectasis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial fistula			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiectasis			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis chronic			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchospasm			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	64 / 13769 (0.46%)	64 / 13756 (0.47%)	
occurrences causally related to treatment / all	0 / 71	1 / 80	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic respiratory failure			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Combined pulmonary fibrosis and emphysema			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	1 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diaphragmatic paralysis			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphonia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	28 / 13769 (0.20%)	18 / 13756 (0.13%)	
occurrences causally related to treatment / all	0 / 28	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea at rest			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	6 / 13769 (0.04%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 7	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysema			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottic cyst			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	10 / 13769 (0.07%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			

subjects affected / exposed	7 / 13769 (0.05%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 7	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiccups			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperventilation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Idiopathic pulmonary fibrosis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal oedema			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal cyst			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal obstruction			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polyps			
subjects affected / exposed	4 / 13769 (0.03%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal turbinate hypertrophy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nocturnal dyspnoea			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal pain			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthopnoea			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal cyst			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pickwickian syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural adhesion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	5 / 13769 (0.04%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural disorder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			

subjects affected / exposed	8 / 13769 (0.06%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	5 / 13769 (0.04%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	5 / 13769 (0.04%)	10 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Productive cough			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary alveolar haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary arterial hypertension			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	20 / 13769 (0.15%)	28 / 13756 (0.20%)	
occurrences causally related to treatment / all	0 / 20	1 / 29	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary fibrosis			

subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary mass			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory disorder			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	16 / 13769 (0.12%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 17	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sleep apnoea syndrome			

subjects affected / exposed	6 / 13769 (0.04%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 6	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stridor			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord leukoplakia			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Acute psychosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Affective disorder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol abuse			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol withdrawal syndrome			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholism			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	4 / 13769 (0.03%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety disorder			
subjects affected / exposed	0 / 13769 (0.00%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety disorder due to a general medical condition			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burnout syndrome			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Conversion disorder			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium tremens			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressed mood			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	15 / 13769 (0.11%)	20 / 13756 (0.15%)	
occurrences causally related to treatment / all	1 / 16	0 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression suicidal			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug abuse			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug dependence			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination, visual			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Major depression			

subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mania			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental disorder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	6 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mood disorder due to a general medical condition			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric decompensation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Personality disorder			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychogenic seizure			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somatic symptom disorder			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	6 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device battery issue			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device breakage			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device dislocation			

subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device failure			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device ineffective			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device leakage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device loosening			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lead dislodgement			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis in device			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ampulla of Vater stenosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune hepatitis			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stenosis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct stone			
subjects affected / exposed	6 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	1 / 5	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary cyst			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	5 / 13769 (0.04%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	0 / 13769 (0.00%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	14 / 13769 (0.10%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 14	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	40 / 13769 (0.29%)	31 / 13756 (0.23%)	
occurrences causally related to treatment / all	1 / 40	0 / 31	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	1 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystochoolangitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	27 / 13769 (0.20%)	23 / 13756 (0.17%)	
occurrences causally related to treatment / all	0 / 28	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis migration			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis obstructive			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cirrhosis alcoholic			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder perforation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder polyp			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cyst			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic fibrosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic steatosis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis alcoholic			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis toxic			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatorenal syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatotoxicity			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertransaminasaemia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaundice			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Porcelain gallbladder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Portal vein thrombosis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subacute hepatic failure			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	11 / 13769 (0.08%)	15 / 13756 (0.11%)	
occurrences causally related to treatment / all	6 / 11	11 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriogram coronary			
subjects affected / exposed	5 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriogram coronary abnormal			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriogram coronary normal			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	6 / 13769 (0.04%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	1 / 6	7 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			

subjects affected / exposed	7 / 13769 (0.05%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	5 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose decreased			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose fluctuation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose increased			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure increased			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac stress test abnormal			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			

subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram ST segment depression			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrocardiogram abnormal			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exercise electrocardiogram abnormal			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
False positive investigation result			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart rate increased			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart rate irregular			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	24 / 13769 (0.17%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	14 / 25	4 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A antibody positive			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A virus test positive			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B antibody positive			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis C virus test positive			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza A virus test positive			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza B virus test positive			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio abnormal			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
International normalised ratio increased			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipase increased			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			
subjects affected / exposed	7 / 13769 (0.05%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	3 / 7	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	0 / 13769 (0.00%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 0	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical observation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial necrosis marker increased			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oxygen saturation decreased			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Precancerous cells present			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress echocardiogram			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid function test abnormal			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased			
subjects affected / exposed	6 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	2 / 7	2 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin I increased			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin T increased			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight increased			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal injury			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum fracture			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia postoperative			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic fistula			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic leak			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic stenosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Animal bite			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Animal scratch			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	8 / 13769 (0.06%)	12 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 10	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic injury			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial bypass thrombosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial injury			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial restenosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula site complication			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropod bite			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Avulsion fracture			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back injury			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbon monoxide poisoning			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cartilage injury			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery restenosis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemical burn of gastrointestinal tract			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chemical poisoning			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Comminuted fracture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	5 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			

subjects affected / exposed	6 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery restenosis			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cranial nerve injury			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	6 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse axonal injury			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dislocation of sternum			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dislocation of vertebra			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endotracheal intubation complication			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extradural haematoma			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye contusion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye injury			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye operation complication			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Face injury			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	17 / 13769 (0.12%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 17	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	4 / 13769 (0.03%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			

subjects affected / exposed	20 / 13769 (0.15%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	1 / 20	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Forearm fracture			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body aspiration			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture displacement			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured ischium			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured sacrum			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft complication			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	6 / 13769 (0.04%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat exhaustion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat stroke			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	11 / 13769 (0.08%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 11	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			

subjects affected / exposed	6 / 13769 (0.04%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ilium fracture			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incomplete spinal fusion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation of wound			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury			
subjects affected / exposed	5 / 13769 (0.04%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	1 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw fracture			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			

subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation postoperative			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney contusion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laceration			
subjects affected / exposed	4 / 13769 (0.03%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament rupture			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb crushing injury			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb fracture			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			

subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb traumatic amputation			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	7 / 13769 (0.05%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medication error			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	8 / 13769 (0.06%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 8	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metal poisoning			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle contusion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle rupture			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck injury			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Open globe injury			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial reocclusion			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery restenosis			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	3 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perirenal haematoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peroneal nerve palsy postoperative			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumoconiosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis chemical			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax traumatic			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post concussion syndrome			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post laminectomy syndrome			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural constipation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	6 / 13769 (0.04%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural myocardial infarction			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural swelling			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic neck syndrome			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative respiratory failure			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative thoracic procedure complication			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound complication			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural complication			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural hypotension			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pain			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pneumothorax			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pubis fracture			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radial head dislocation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation mucositis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiation oesophagitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			

subjects affected / exposed	7 / 13769 (0.05%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	4 / 13769 (0.03%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scapula fracture			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sacroiliac fracture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skeletal injury			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin abrasion			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fractured base			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Snake bite			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column injury			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord injury			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord injury lumbar			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic injury			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stab wound			

subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sternal fracture			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous haematoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	6 / 13769 (0.04%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 6	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon injury			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	6 / 13769 (0.04%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			

subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	7 / 13769 (0.05%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 13769 (0.00%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant failure			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic arthritis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic fracture			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haematoma			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haemothorax			

subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic shock			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic ulcer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulnar nerve injury			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	5 / 13769 (0.04%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stricture postoperative			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular bypass dysfunction			

subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft complication			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft occlusion			
subjects affected / exposed	2 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft thrombosis			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular procedure complication			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound dehiscence			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound evisceration			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound necrosis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound secretion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Adenomatous polyposis coli			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous malformation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial septal defect			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbohydrate metabolism disorder			

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exomphalos			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal dystrophy			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal arteriovenous malformation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hereditary motor and sensory neuropathy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertrophic cardiomyopathy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial lipoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subependymal nodular heterotopia			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	6 / 13769 (0.04%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 6	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute left ventricular failure			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	11 / 13769 (0.08%)	23 / 13756 (0.17%)	
occurrences causally related to treatment / all	0 / 11	1 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	208 / 13769 (1.51%)	221 / 13756 (1.61%)	
occurrences causally related to treatment / all	4 / 240	6 / 250	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	233 / 13769 (1.69%)	278 / 13756 (2.02%)	
occurrences causally related to treatment / all	4 / 273	3 / 314	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			

subjects affected / exposed	10 / 13769 (0.07%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia supraventricular			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis coronary artery			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteritis coronary			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	119 / 13769 (0.86%)	132 / 13756 (0.96%)	
occurrences causally related to treatment / all	0 / 157	2 / 155	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	25 / 13769 (0.18%)	17 / 13756 (0.12%)	
occurrences causally related to treatment / all	0 / 27	1 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	16 / 13769 (0.12%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 16	1 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block first degree			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			
subjects affected / exposed	7 / 13769 (0.05%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bifascicular block			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradyarrhythmia			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	10 / 13769 (0.07%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	1 / 10	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block bilateral			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block right			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac aneurysm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	3 / 13769 (0.02%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac asthma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure acute			
subjects affected / exposed	13 / 13769 (0.09%)	10 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 13	1 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			

subjects affected / exposed	66 / 13769 (0.48%)	66 / 13756 (0.48%)	
occurrences causally related to treatment / all	0 / 71	1 / 73	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	50 / 13769 (0.36%)	47 / 13756 (0.34%)	
occurrences causally related to treatment / all	0 / 53	0 / 56	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	46 / 13769 (0.33%)	37 / 13756 (0.27%)	
occurrences causally related to treatment / all	0 / 48	0 / 40	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac flutter			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiomyopathy			

subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiotoxicity			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiorenal syndrome			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiovascular disorder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congestive cardiomyopathy			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	32 / 13769 (0.23%)	46 / 13756 (0.33%)	
occurrences causally related to treatment / all	0 / 33	0 / 48	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			

subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery thrombosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diastolic dysfunction			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dressler's syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extrasystoles			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart alternation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heart valve incompetence			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive cardiomyopathy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive heart disease			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracardiac thrombus			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cardiomyopathy			
subjects affected / exposed	7 / 13769 (0.05%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	1 / 13769 (0.01%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microvascular coronary artery disease			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			
subjects affected / exposed	11 / 13769 (0.08%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 12	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve stenosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			

subjects affected / exposed	31 / 13769 (0.23%)	31 / 13756 (0.23%)	
occurrences causally related to treatment / all	1 / 31	1 / 31	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	26 / 13769 (0.19%)	21 / 13756 (0.15%)	
occurrences causally related to treatment / all	0 / 26	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial necrosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocarditis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	7 / 13769 (0.05%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 7	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prinzmetal angina			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulseless electrical activity			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhythm idioventricular			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Silent myocardial infarction			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus arrest			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus bradycardia			
subjects affected / exposed	4 / 13769 (0.03%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	17 / 13769 (0.12%)	18 / 13756 (0.13%)	
occurrences causally related to treatment / all	0 / 17	0 / 18	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress cardiomyopathy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			

subjects affected / exposed	9 / 13769 (0.07%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 10	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Torsade de pointes			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			
subjects affected / exposed	4 / 13769 (0.03%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	7 / 13769 (0.05%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	12 / 13769 (0.09%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 12	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular hypertrophy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachyarrhythmia			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			

subjects affected / exposed	23 / 13769 (0.17%)	27 / 13756 (0.20%)	
occurrences causally related to treatment / all	0 / 30	0 / 33	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amnesia			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amputation stump pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amyotrophic lateral sclerosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aphasia			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Apraxia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arachnoid cyst			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balance disorder			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia infarction			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basilar artery aneurysm			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basilar artery stenosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			
subjects affected / exposed	5 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery disease			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			
subjects affected / exposed	3 / 13769 (0.02%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			

subjects affected / exposed	37 / 13769 (0.27%)	39 / 13756 (0.28%)	
occurrences causally related to treatment / all	2 / 39	0 / 43	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	6 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cauda equina syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar ataxia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral arteriosclerosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery occlusion			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery stenosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral atrophy			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haematoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	5 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			
subjects affected / exposed	1 / 13769 (0.01%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral thrombosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral vasoconstriction			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	25 / 13769 (0.18%)	21 / 13756 (0.15%)	
occurrences causally related to treatment / all	1 / 26	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular disorder			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular insufficiency			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical cord compression			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical myelopathy			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical radiculopathy			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicogenic headache			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complex partial seizures			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Demyelinating polyneuropathy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	4 / 13769 (0.03%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	15 / 13769 (0.11%)	19 / 13756 (0.14%)	
occurrences causally related to treatment / all	1 / 15	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dystonia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis autoimmune			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			

subjects affected / exposed	5 / 13769 (0.04%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	0 / 13769 (0.00%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	9 / 13769 (0.07%)	17 / 13756 (0.12%)	
occurrences causally related to treatment / all	0 / 9	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiplegic migraine			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertonia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic coma			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic encephalopathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic unconsciousness			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
IIIrd nerve paralysis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	3 / 13769 (0.02%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial mass			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cerebral infarction			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	6 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar infarction			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar stroke			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lethargy			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			
subjects affected / exposed	2 / 13769 (0.01%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	1 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbosacral radiculopathy			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meralgia paraesthetica			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine with aura			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoparesis			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Motor neurone disease			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelopathy			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nerve compression			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuralgia			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuritis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroglycopenia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuromuscular pain			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathy peripheral			
subjects affected / exposed	5 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 5	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraesthesia			
subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraparesis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paresis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinsonism			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral motor neuropathy			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peroneal nerve palsy			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy idiopathic progressive			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postictal state			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	9 / 13769 (0.07%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychomotor hyperactivity			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudoradicular syndrome			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Quadriplegia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radicular syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	6 / 13769 (0.04%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retrograde amnesia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	14 / 13769 (0.10%)	10 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 14	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sedation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			

subjects affected / exposed	8 / 13769 (0.06%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 9	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Speech disorder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal claudication			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stroke in evolution			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural effusion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	63 / 13769 (0.46%)	56 / 13756 (0.41%)	
occurrences causally related to treatment / all	2 / 64	0 / 59	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tarsal tunnel syndrome			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tension headache			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic outlet syndrome			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient global amnesia			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	42 / 13769 (0.31%)	36 / 13756 (0.26%)	
occurrences causally related to treatment / all	1 / 43	0 / 36	
deaths causally related to treatment / all	0 / 0	0 / 0	
Unresponsive to stimuli			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular encephalopathy			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral artery occlusion			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo CNS origin			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual field defect			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vocal cord paralysis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	27 / 13769 (0.20%)	27 / 13756 (0.20%)	
occurrences causally related to treatment / all	0 / 28	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia of chronic disease			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune haemolytic anaemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			

subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	2 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochromic anaemia			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune thrombocytopenic purpura			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	9 / 13769 (0.07%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	1 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy mediastinal			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normochromic normocytic anaemia			
subjects affected / exposed	4 / 13769 (0.03%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pernicious anaemia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polycythaemia			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spleen disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness neurosensory			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deafness unilateral			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoacusis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniere's disease			

subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inner ear inflammation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otorrhoea			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden hearing loss			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	9 / 13769 (0.07%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 9	1 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tinnitus			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	7 / 13769 (0.05%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular ischaemia			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Angle closure glaucoma			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blepharochalasis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	15 / 13769 (0.11%)	22 / 13756 (0.16%)	
occurrences causally related to treatment / all	0 / 16	0 / 24	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract nuclear			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryoadenitis acquired			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ectropion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid ptosis			

subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iridocyclitis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular degeneration			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular fibrosis			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular myasthenia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmoplegia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pterygium			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			
subjects affected / exposed	3 / 13769 (0.02%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal tear			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vascular disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strabismus			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uveitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual acuity reduced			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual impairment			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous floaters			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal discomfort			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	11 / 13769 (0.08%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal distension			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			

subjects affected / exposed	12 / 13769 (0.09%)	19 / 13756 (0.14%)	
occurrences causally related to treatment / all	1 / 13	3 / 22	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	12 / 13769 (0.09%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 12	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall haematoma			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcoholic pancreatitis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal incontinence			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anastomotic ulcer perforation			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Barrett's oesophagus			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastritis			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coeliac artery stenosis			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	6 / 13769 (0.04%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	10 / 13769 (0.07%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 11	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			
subjects affected / exposed	2 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic fistula			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	9 / 13769 (0.07%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	1 / 9	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	9 / 13769 (0.07%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	4 / 13769 (0.03%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal haemorrhagic			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			

subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis			
subjects affected / exposed	1 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	7 / 13769 (0.05%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	1 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiplonic appendagitis			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Faecaloma			

subjects affected / exposed	4 / 13769 (0.03%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Food poisoning			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cyst			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	9 / 13769 (0.07%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	7 / 13769 (0.05%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer perforation			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			

subjects affected / exposed	19 / 13769 (0.14%)	17 / 13756 (0.12%)	
occurrences causally related to treatment / all	0 / 19	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis alcoholic			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenal haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroduodenitis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal angiodysplasia haemorrhagic			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			

subjects affected / exposed	27 / 13769 (0.20%)	16 / 13756 (0.12%)	
occurrences causally related to treatment / all	0 / 27	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal polyp haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal ulcer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal ulcer haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	14 / 13769 (0.10%)	15 / 13756 (0.11%)	
occurrences causally related to treatment / all	0 / 14	1 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic erosive gastritis			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Haemorrhoidal haemorrhage		
subjects affected / exposed	3 / 13769 (0.02%)	5 / 13756 (0.04%)
occurrences causally related to treatment / all	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0
Haemorrhoids		
subjects affected / exposed	6 / 13769 (0.04%)	10 / 13756 (0.07%)
occurrences causally related to treatment / all	0 / 6	0 / 10
deaths causally related to treatment / all	0 / 0	0 / 0
Haemorrhoids thrombosed		
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hernial eventration		
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Hiatus hernia		
subjects affected / exposed	9 / 13769 (0.07%)	3 / 13756 (0.02%)
occurrences causally related to treatment / all	0 / 9	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Ileus		
subjects affected / exposed	6 / 13769 (0.04%)	7 / 13756 (0.05%)
occurrences causally related to treatment / all	0 / 6	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 0
Impaired gastric emptying		
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)
occurrences causally related to treatment / all	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Ileus paralytic		

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated inguinal hernia			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammatory bowel disease			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	32 / 13769 (0.23%)	22 / 13756 (0.16%)	
occurrences causally related to treatment / all	0 / 34	0 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal dilatation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal fistula			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	3 / 13769 (0.02%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal prolapse			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal fluid collection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haematoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intussusception			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal obstruction			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal ulcer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	10 / 13769 (0.07%)	16 / 13756 (0.12%)	
occurrences causally related to treatment / all	0 / 10	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukoplakia oral			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mallory-Weiss syndrome			

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric arterial occlusion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric artery stenosis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric artery thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesenteric vein thrombosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	1 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Odynophagia			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal achalasia			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal food impaction			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal obstruction			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal spasm			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal stenosis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			

subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis ulcerative			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palatal swelling			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic cyst			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic necrosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic phlegmon			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic pseudocyst			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			

subjects affected / exposed	10 / 13769 (0.07%)	16 / 13756 (0.12%)
occurrences causally related to treatment / all	1 / 10	1 / 17
deaths causally related to treatment / all	0 / 0	0 / 0
Pancreatitis acute		
subjects affected / exposed	14 / 13769 (0.10%)	22 / 13756 (0.16%)
occurrences causally related to treatment / all	1 / 16	5 / 28
deaths causally related to treatment / all	0 / 0	0 / 0
Pancreatitis chronic		
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Pancreatitis necrotising		
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)
occurrences causally related to treatment / all	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pancreatolithiasis		
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Peptic ulcer		
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)
occurrences causally related to treatment / all	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Peptic ulcer haemorrhage		
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)
occurrences causally related to treatment / all	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Periodontal disease		
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peritoneal haematoma		

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	6 / 13769 (0.04%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal polyp			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reflux gastritis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retching			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal fibrosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haemorrhage			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salivary gland enlargement			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	4 / 13769 (0.03%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestine ulcer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strangulated umbilical hernia			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress ulcer			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis mesenteric vessel			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue cyst			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue oedema			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth disorder			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth impacted			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	10 / 13769 (0.07%)	14 / 13756 (0.10%)	
occurrences causally related to treatment / all	0 / 10	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	13 / 13769 (0.09%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 13	1 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varices oesophageal			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Volvulus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	4 / 13769 (0.03%)	10 / 13756 (0.07%)	
occurrences causally related to treatment / all	1 / 4	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis allergic			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis contact			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis exfoliative			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatomyositis			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	6 / 13769 (0.04%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry skin			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema nummular			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Excessive granulation tissue			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Excessive skin			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Henoch-Schonlein purpura			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperhidrosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ingrowing nail			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lichen myxoedematosus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lichen planus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papulopustular rosacea			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pemphigoid			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus generalised			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scar pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin exfoliation			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	5 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stasis dermatitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous emphysema			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Swelling face			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urticaria			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	64 / 13769 (0.46%)	64 / 13756 (0.47%)	
occurrences causally related to treatment / all	3 / 69	0 / 66	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute prerenal failure			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Azotaemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder dilatation			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder diverticulum			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neck obstruction			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder obstruction			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder outlet obstruction			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder spasm			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder tamponade			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus bladder			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urethral			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	3 / 13769 (0.02%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	17 / 13769 (0.12%)	15 / 13756 (0.11%)	
occurrences causally related to treatment / all	1 / 17	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis haemorrhagic			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysuria			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			
subjects affected / exposed	2 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 2	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulonephritis chronic			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerulonephritis membranous			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	17 / 13769 (0.12%)	12 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 19	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage urinary tract			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			

subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	16 / 13769 (0.12%)	29 / 13756 (0.21%)	
occurrences causally related to treatment / all	0 / 16	1 / 31	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurogenic bladder			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nocturia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive uropathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prerenal failure			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelocaliectasis			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	1 / 13769 (0.01%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	3 / 13769 (0.02%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst haemorrhage			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	4 / 13769 (0.03%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal infarct			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			

subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal pain			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress urinary incontinence			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric rupture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric stenosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	9 / 13769 (0.07%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	5 / 13769 (0.04%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence			

subjects affected / exposed	1 / 13769 (0.01%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	14 / 13769 (0.10%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 14	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinoma			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenal mass			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basedow's disease			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism primary			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoadosteronism			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid mass			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	16 / 13769 (0.12%)	18 / 13756 (0.13%)	
occurrences causally related to treatment / all	0 / 16	1 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	11 / 13769 (0.08%)	13 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 11	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthropathy			

subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	30 / 13769 (0.22%)	30 / 13756 (0.22%)	
occurrences causally related to treatment / all	0 / 32	0 / 31	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone deformity			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondrocalcinosis pyrophosphate			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondropathy			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			

subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic amyotrophy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dupuytren's contracture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enthesopathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exostosis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exostosis of jaw			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facet joint syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoroacetabular impingement			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibromyalgia			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	7 / 13769 (0.05%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture nonunion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin pain			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	8 / 13769 (0.06%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc displacement			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	22 / 13769 (0.16%)	24 / 13756 (0.17%)	
occurrences causally related to treatment / all	0 / 23	0 / 26	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw cyst			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint adhesion			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint effusion			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint instability			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint range of motion decreased			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint swelling			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb discomfort			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	21 / 13769 (0.15%)	17 / 13756 (0.12%)	
occurrences causally related to treatment / all	0 / 21	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mobility decreased			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monarthrititis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle spasms			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	49 / 13769 (0.36%)	37 / 13756 (0.27%)	
occurrences causally related to treatment / all	0 / 54	1 / 40	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal pain			
subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal stiffness			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia			
subjects affected / exposed	8 / 13769 (0.06%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	4 / 8	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myalgia intercostal			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myofascitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopathy			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	4 / 13769 (0.03%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodal osteoarthritis			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	91 / 13769 (0.66%)	100 / 13756 (0.73%)	
occurrences causally related to treatment / all	1 / 93	0 / 109	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondritis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteochondrosis			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	4 / 13769 (0.03%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporotic fracture			

subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	8 / 13769 (0.06%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in jaw			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patellofemoral pain syndrome			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyositis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudarthrosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	4 / 13769 (0.03%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	1 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatoid arthritis			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	1 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	8 / 13769 (0.06%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seronegative arthritis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	6 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal instability			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	9 / 13769 (0.07%)	12 / 13756 (0.09%)	
occurrences causally related to treatment / all	0 / 9	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	8 / 13769 (0.06%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 8	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondyloarthropathy			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolysis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sympathetic posterior cervical syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Symphysiolysis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	1 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Temporomandibular joint syndrome			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon necrosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendonitis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Trigger finger			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral osteophyte			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal sepsis			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess bacterial			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	10 / 13769 (0.07%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 10	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess of eyelid			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess of salivary gland			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess soft tissue			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Amoebic dysentery			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	2 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendiceal abscess			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	20 / 13769 (0.15%)	14 / 13756 (0.10%)	
occurrences causally related to treatment / all	0 / 20	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			

subjects affected / exposed	2 / 13769 (0.01%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteritis infective			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial pericarditis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial prostatitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial pyelonephritis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteroides bacteraemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Beta haemolytic streptococcal infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast abscess			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	17 / 13769 (0.12%)	30 / 13756 (0.22%)	
occurrences causally related to treatment / all	1 / 17	1 / 30	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis bacterial			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burkholderia cepacia complex infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Burkholderia pseudomallei infection			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis infective			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbuncle			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Catheter site infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis gangrenous			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	39 / 13769 (0.28%)	28 / 13756 (0.20%)	
occurrences causally related to treatment / all	1 / 43	0 / 28	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis infective			

subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatitis B			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic sinusitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	6 / 13769 (0.04%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	3 / 13769 (0.02%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colonic abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Creutzfeldt-Jakob disease			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	3 / 13769 (0.02%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis escherichia			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	1 / 13769 (0.01%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	2 / 13769 (0.01%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	16 / 13769 (0.12%)	26 / 13756 (0.19%)	
occurrences causally related to treatment / all	0 / 18	0 / 29	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis intestinal haemorrhagic			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema infected			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic pneumonia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Empyema			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis viral			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis bacterial			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis haemophilus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endophthalmitis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis infectious			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterobacter bacteraemia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal sepsis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiglottitis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	16 / 13769 (0.12%)	19 / 13756 (0.14%)	
occurrences causally related to treatment / all	0 / 17	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipeloid			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	1 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungal peritonitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Furuncle			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder empyema			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			

subjects affected / exposed	6 / 13769 (0.04%)	12 / 13756 (0.09%)
occurrences causally related to treatment / all	0 / 8	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 0
Gastritis viral		
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis		
subjects affected / exposed	19 / 13769 (0.14%)	14 / 13756 (0.10%)
occurrences causally related to treatment / all	0 / 20	0 / 14
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis adenovirus		
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis bacterial		
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis clostridial		
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis rotavirus		
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis salmonella		
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)
occurrences causally related to treatment / all	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis viral		

subjects affected / exposed	3 / 13769 (0.02%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival abscess			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft infection			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1N1 influenza			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis C			
subjects affected / exposed	3 / 13769 (0.02%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis E			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	5 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implant site infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected bite			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected cyst			

subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			
subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection in an immunocompromised host			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious colitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious pleural effusion			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	3 / 13769 (0.02%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective tenosynovitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			

subjects affected / exposed	9 / 13769 (0.07%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney infection			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngitis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	6 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	14 / 13769 (0.10%)	15 / 13756 (0.11%)	
occurrences causally related to treatment / all	1 / 15	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection viral			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung abscess			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	5 / 13769 (0.04%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mastoiditis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device site infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis bacterial			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis pneumococcal			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle abscess			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurosyphilis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nosocomial infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmic herpes zoster			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral fungal infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			

subjects affected / exposed	2 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	16 / 13769 (0.12%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	1 / 18	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis acute			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis chronic			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa bacterial			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreas infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parotitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic abscess			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perineal abscess			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periodontitis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perirectal abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	4 / 13769 (0.03%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis bacterial			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngeal abscess			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis streptococcal			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal sepsis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	147 / 13769 (1.07%)	152 / 13756 (1.10%)	
occurrences causally related to treatment / all	1 / 154	1 / 162	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia adenoviral			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	18 / 13769 (0.13%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 18	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia legionella			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia influenzal			

subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia staphylococcal			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			
subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural pneumonia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural sepsis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative abscess			
subjects affected / exposed	0 / 13769 (0.00%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			

subjects affected / exposed	3 / 13769 (0.02%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic abscess			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomembranous colitis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoas abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	10 / 13769 (0.07%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 12	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			

subjects affected / exposed	6 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	1 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis chronic			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyonephrosis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	8 / 13769 (0.06%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinovirus infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonellosis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salpingitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	21 / 13769 (0.15%)	31 / 13756 (0.23%)	
occurrences causally related to treatment / all	0 / 22	0 / 32	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	6 / 13769 (0.04%)	9 / 13756 (0.07%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin bacterial infection			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			

subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spermatic cord funiculitis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic abscess			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal abscess			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	1 / 13769 (0.01%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal sepsis			

subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tick-borne viral encephalitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheitis			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tuberculosis			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	6 / 13769 (0.04%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection bacterial			
subjects affected / exposed	0 / 13769 (0.00%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteritis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	41 / 13769 (0.30%)	37 / 13756 (0.27%)	
occurrences causally related to treatment / all	0 / 48	0 / 42	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	7 / 13769 (0.05%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	12 / 13769 (0.09%)	15 / 13756 (0.11%)	
occurrences causally related to treatment / all	0 / 13	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular neuronitis			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			

subjects affected / exposed	4 / 13769 (0.03%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral myocarditis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral pericarditis			
subjects affected / exposed	2 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval abscess			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound abscess			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	6 / 13769 (0.04%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection bacterial			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection staphylococcal			

subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound sepsis			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Abnormal loss of weight			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cachexia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	16 / 13769 (0.12%)	18 / 13756 (0.13%)	
occurrences causally related to treatment / all	0 / 17	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	61 / 13769 (0.44%)	56 / 13756 (0.41%)	
occurrences causally related to treatment / all	2 / 71	3 / 60	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	6 / 13769 (0.04%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 7	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			

subjects affected / exposed	10 / 13769 (0.07%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	0 / 10	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic metabolic decompensation			
subjects affected / exposed	2 / 13769 (0.01%)	3 / 13756 (0.02%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	3 / 13769 (0.02%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid retention			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glucose tolerance impaired			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	6 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperammonaemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			

subjects affected / exposed	8 / 13769 (0.06%)	8 / 13756 (0.06%)	
occurrences causally related to treatment / all	1 / 8	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperinsulinaemic hypoglycaemia			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	10 / 13769 (0.07%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypernatraemia			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperosmolar hyperglycaemic state			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			
subjects affected / exposed	1 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	17 / 13769 (0.12%)	11 / 13756 (0.08%)	
occurrences causally related to treatment / all	0 / 17	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia unawareness			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			

subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	6 / 13769 (0.04%)	7 / 13756 (0.05%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	5 / 13769 (0.04%)	5 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovitaminosis			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	0 / 13769 (0.00%)	2 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	2 / 13769 (0.01%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			

subjects affected / exposed	3 / 13769 (0.02%)	6 / 13756 (0.04%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 13769 (0.00%)	1 / 13756 (0.01%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	12 / 13769 (0.09%)	4 / 13756 (0.03%)	
occurrences causally related to treatment / all	0 / 12	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin B12 deficiency			
subjects affected / exposed	1 / 13769 (0.01%)	0 / 13756 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Evolocumab	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3500 / 13769 (25.42%)	3438 / 13756 (24.99%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	1069 / 13769 (7.76%)	1157 / 13756 (8.41%)	
occurrences (all)	1193	1315	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1067 / 13769 (7.75%)	1021 / 13756 (7.42%)	
occurrences (all)	1364	1260	
Upper respiratory tract infection			
subjects affected / exposed	692 / 13769 (5.03%)	649 / 13756 (4.72%)	
occurrences (all)	807	788	
Metabolism and nutrition disorders			

Diabetes mellitus			
subjects affected / exposed	1156 / 13769 (8.40%)	1096 / 13756 (7.97%)	
occurrences (all)	1255	1200	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 September 2012	<ul style="list-style-type: none">• add testing for prior or existing Hepatitis C virus (HCV) infection in high risk individuals and monitoring of viral load in those who show evidence thereof• add the exclusion of family history of hereditary muscular disorders• add instruction that investigators will ask study subjects to promptly report muscle pain, cramps, or weakness especially if accompanied by malaise or fever and provide further detail regarding stopping rules for atorvastatin and investigational product in case of elevated creatine kinase levels• provide guidance regarding actions to take if the subject requires treatment with a strong CYP3A4 inhibitor while on study• add baseline electrocardiogram (ECG) in triplicate for all subjects, not just at sites provided with centralized ECG services equipment• add a description of composition and role of the Clinical Events Committee (CEC)• add serum pregnancy testing at the randomization visit (day 1) for women of childbearing potential• add ezetimibe use at baseline to covariates
24 September 2012	<ul style="list-style-type: none">• add study name FOURIER• add phase 3 formulation information for IP and introduce the prefilled autoinjector/pen for administration of the IP• modify Schedule of Assessments for reduced visit frequency and IP administration by autoinjector/pen at locations external to study center• prolong the time investigators are not to perform non-protocol testing of blinded analytes to 12 weeks after last IP administration or end of study, whichever is later• provide more specificity about adjudicated clinical events• add information about the study Executive Committee and Lipid Monitoring Committee• add reporting requirements for product/device complaints• replace routine visits with administration of IP external to the study center• extend maximal duration of screening from 12 to 15 weeks• add HCV testing at enrollment and evaluation of viral load during the study, if positive, for subjects with a history of HCV infection• increase planned sites to 1000• clarify definition of metabolic syndrome in inclusion criteria• add homozygous familial hypercholesterolemia and LDL or plasma apheresis within 12 months to exclusions• add Israel and Australasia• clarify that all cause death, MI, stroke, revascularization, hospitalization for unstable angina, hospitalization for HF, and TIA are not considered SAEs in this study, but will be handled as efficacy endpoints• clarify that Amgen will review all fatal endpoints to evaluate whether the cause of death is due to a SAE that is a specific concern for a protein therapeutic or which may be individually informative. If detected, Amgen will notify the investigator to submit a SAE eCRF within 24 hours of Amgen's notification.• change time to first hospitalization for worsening HF secondary endpoint to composite endpoint of time to CV death or hospitalization for HF• add secondary endpoint of time to ischemic fatal or non-fatal stroke or TIA• modify lab assessment schedule, including collection biomarker samples

12 December 2012	<ul style="list-style-type: none"> • clarify that the reporting process for potential endpoints and the information collected corresponds to the requirements and the information collected for serious adverse events • clarify that the physical exam should include a neurological exam • increase the upper age limit to 85 years from 80 years • add notification of the investigator if triglycerides are > 1000 mg/dL • add collection of the reason why subjects switch investigational product administration regimen • add alert threshold for elevated triglycerides • add measurement of urine microalbumin at week 48 and end of study
16 July 2013	<ul style="list-style-type: none"> • allow statins other than atorvastatin for background lipid lowering therapy • redefine the acceptable lipid therapy, including changes in allowed lipid therapy other than statins • include symptomatic peripheral arterial disease as evidence of cardiovascular disease • minor modifications of the risk factors for eligibility • add the automated mini doser (also referred to as the 3.5 mL personal injector) to the investigational product administration devices • increase the number of study centers • allow QM dosing from initiation of IP administration • add option of an informed consent for screening and lipid therapy titration only • update the section on withdrawal from treatment • update sections on adverse event and serious adverse event reporting
28 August 2014	<ul style="list-style-type: none"> • increase enrollment from approximately 22,500 to up to approximately 27,500 randomized subjects • update key sponsor contact information • add the product name evolocumab
29 September 2015	<ul style="list-style-type: none"> • add the major components of the primary objective and endpoint as separate secondary objectives and endpoints • revise statistical testing to account for the additional secondary endpoints • add adjudication of new onset diabetes. • revise section on prohibited treatments during the study to account for recent results of another trial (IMPROVE-IT) and enable addition of ezetimibe in subjects experiencing an acute coronary syndrome during the study. Ezetimibe was not prohibited prior to this amendment, as long as subjects were on stable doses at the time of randomization. • add HbA1c to blood draws at week 24 and Q24W visit to assist detection of new onset diabetes. • revise end-of-study procedures to enable more flexibility for sites to schedule end-of-study visits and add a safety contact at 30 days after last administration of IP if the end-of-study visit is less than 30 days after last IP. • add text for the collection of vital status information.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported